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ABSTRACT
Purpose: Cdc7 is a serine/threonine kinase which is responsible for the ‘firing’ of 
replication origins leading to initiation of DNA replication. Inhibition or depletion of 
Cdc7 in normal cells triggers a DNA origin activation checkpoint causing a reversible 
G1 arrest. Here we investigate Cdc7 as a novel therapeutic target in pancreatic cancer.
Experimental design: Cdc7 target validation was performed by immunoexpression 
profiling in a cohort of 73 patients with pancreatic adenocarcinoma including 24 
controls. Secondly Cdc7 kinase was targeted in Capan-1 and PANC-1 pancreatic cancer 
cell line models using either an siRNA against Cdc7 or alternatively a small molecule 
inhibitor (SMI) of Cdc7 (PHA-767491).
Results: Cdc7 was significantly overexpressed in pancreatic adenocarcinoma 
compared to benign pancreatic tissue (median LI 34.3% vs. 1.3%; P<0.0001). Cdc7 
knockdown using siRNA in Capan-1 and PANC-1 cells resulted in marked apoptotic 
cell death when compared with control cells. A prominent sub-G1 peak was seen on 
flow cytometry (sub-G1 51% vs. 3% and 45% vs. 0.7% in Capan-1 and PANC-1 cells, 
respectively). Annexin V labelling confirmed apoptosis in 64% vs. 11% and 75% 
vs. 8%, respectively. Western blotting showed cleavage of PARP-1 and caspase-3 
and presence of γH2A.X. TUNEL assay showed strong staining in treated cells. These 
results were mirrored following Cdc7 kinase inhibition with PHA-767491.
Conclusions: Our findings show that Cdc7 is a potent anti-cancer target in 
pancreatic adenocarcinoma and that Cdc7 immunoexpression levels might be used 
as a companion diagnostic to predict response to therapeutic siRNAs or SMIs directed 
against this kinase.
INTRODUCTION
Adenocarcinoma of the pancreas is one of the 
top 10 leading causes of cancer deaths [1, 2]. Surgical 
resection provides potential for cure but is possible 
in only a minority of subjects. Even after resection, 
the median survival is limited to 10–20 months and 
only 10-35% of resected patients survive five years or 
more [3–6]. Palliative chemotherapy is associated with 
limited improvements in quality of life and survival 
when compared with best supportive care [7, 8], but 
despite improvements in imaging, surgical techniques 
and chemotherapy, overall survival has not improved 
appreciably in the last few decades [1, 2].
An alternative approach for the treatment of 
pancreatic cancer is the targeting of the DNA replication 
initiation machinery which acts as a convergence point 
for upstream oncogenic signaling pathways [9]. The 
initiation of DNA synthesis can be regarded as a final and 
critical step in growth regulatory control and therefore a 
potentially potent anti-cancer target [10]. Cdc7 kinase is 
a core component of this machinery and is therefore an 
attractive target for therapeutic intervention strategies. 
During late mitosis and early G1 phase, the replication 
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licensing factors (RLF) ORC, Cdc6, Cdt1, and Mcm2-7 
assemble into prereplicative complexes (pre-RCs), which 
render replication origins “licensed” for DNA synthesis 
during S phase [11, 12]. The six Mcm2-7 proteins 
function as a replicative helix, unwinding the template 
DNA, with Cdc6 and Cdt1 acting as clamp loaders for 
this ring-shaped heterohexameric complex [13–15]. At the 
transition from G1 to S phase, licensed replication origins 
are “fired” by the concerted action of CDKs and Dbf4-
dependent kinase. Cdc7 phosphorylates the Mcm 2,4 and 
6 subunits, thereby inducing a conformational change 
that stimulates MCM helicase activity. The formation 
of an active helicase leads to recruitment of additional 
factors, including Cdc45 and the four subunit GINS 
complex [16–18]. Once activated the MCM helicase 
unwinds double-stranded DNA at replication origins to 
generate a single-stranded DNA template required to 
recruit the DNA synthesis machinery including RPA, 
PCNA and DNA polymerase α-primase [12]. During S 
phase, Cdc7 kinase and cyclin-dependent kinases induce 
a conformational change in the prereplicative complex, 
resulting in recruitment of additional initiator proteins 
that collectively promote DNA unwinding, recruitment of 
DNA polymerases and the establishment of bi-directional 
replication forks.
The interest in Cdc7 as a therapeutic target 
comes from the observation that depleting Cdc7 levels 
using siRNA, or alternatively inhibiting Cdc7 kinase 
activity in cancer cells, results in only limited numbers 
of replication forks being established during S phase, 
culminating in fork stalling and/or collapse followed by 
apoptotic cell death [19–22]. Intriguingly, the specificity 
of this approach relates to the fact that normal somatic 
cells avoid entering a lethal S phase under Cdc7 rate 
limiting conditions by engaging a DNA origin activation 
checkpoint response that reversibly arrests cells in G1 
phase until Cdc7 levels are restored following removal of 
the Cdc7 targeting agent [19, 23]. Our studies and those of 
other groups have previously shown that this checkpoint 
is p53 dependent [19–21, 23]. More recently we have 
determined that this checkpoint is also dependent on a 
number of additional tumour suppressor genes commonly 
inactivated in solid tumours [23]. We have shown that 
this DNA checkpoint response is mediated via three 
signalling axes coordinated through the transcription 
factor FoxO3a (Figure 1). In arrested cells, FoxO3a 
activates the ARF-|Hdm2-|p53-p21 pathway and mediates 
p15INK4B upregulation; p53 in turn activates expression 
of the Wnt/b-catenin signalling antagonist Dkk3, leading 
to Myc and cyclin D1 downregulation. The resulting loss 
of CDK activity inactivates the Rb-E2F pathway and 
overrides the G1-S transcriptional programme. Notably 
we observed no redundancy in these checkpoint effector 
axes, meaning that any tumours harbouring inactivating 
mutations in any of the tumour suppressor genes namely 
p53, p21, Dkk3, ARF, Hdm2, FoxO3a, p15, p27 and Rb 
are susceptible to Cdc7 targeting agents. Taken together 
these findings indicate that targeting Cdc7 constitutes a 
synthetic lethality driven approach in tumour backgrounds 
harbouring commonly mutated tumour suppressor genes.
Interestingly, inactivating mutations in p53 not only 
disrupt the DNA origin activation checkpoint making 
tumours susceptible to targeting of Cdc7, but also result 
in increased expression of the Cdc7 anti-cancer target 
thus potentially increasing therapeutic efficacy. In a 
study of 62 human cancer cell lines, Cdc7 was found to 
be increased in ~50% of these lines relative to β-actin 
with levels in normal primary cell lines either very low 
or absent [24]. Notably, a strong association between 
high Cdc7 expression levels and mutated TP53 was 
observed in which 90% of mutant p53 cancer cell lines 
overexpressed Cdc7.
The cancer specific killing following Cdc7 targeting 
has generated great interest in the development of 
therapeutic Cdc7 small molecule inhibitors. For example, 
PHA-767491 (Nerviano Medical Sciences, Nerviano, 
Italy), a dual Cdc7/Cdk9 inhibitor, has been shown to have 
activity by inducing apoptosis in a wide variety of cancer 
cell lines. Furthermore, in human HL60 leukemia human 
tumours implanted subcutaneously into nude mouse 
models, there was inhibition of tumour growth, and even 
regression of tumours in some animals, when treated with 
PHA-767491 [22]. In another study, chronic lymphocytic 
leukaemia (CLL) cells were taken from the peripheral 
blood of patients with CLL and treated with PHA-767491. 
In all samples taken from 27 different patients with both 
favourable and unfavourable prognostic markers, PHA-
767491 induced apoptosis of the CLL cells [25].
The recent advances in our understanding of the 
DNA replication initiation machinery and its clinical 
translational exploitation in terms of anti-cancer therapy 
raise the important question as to whether targeting 
Cdc7 might be of clinical benefit in pancreatic cancer 
for which therapeutic options are limited. Importantly, 
70% of pancreatic adenocarcinoma tumours have been 
shown to have inactivating mutations of p53, one of 
the highest frequencies amongst all cancers for this 
tumour suppressor [26, 27]. Moreover, pancreatic 
cancers commonly harbor mutations in additional 
tumour suppressor genes encoding for p14ARF and 
p16INK4A, p15INK4B and p27Kip1; key constituent proteins 
encompassing all three effector arms of the DNA origin 
activation checkpoint [28–33]. It might therefore be 
postulated that these tumours will be highly sensitive 
to Cdc7 targeted therapies and secondly that the Cdc7 
target protein will be expressed at high levels in this 
tumour type. In this study we therefore set out to assess 
expression of the target protein Cdc7 in pancreatic cancer 
(target validation) and to test therapeutic anti-cancer 
potential by targeting Cdc7 kinase in pancreatic cancer 
cell line models using both siRNA and the PHA-767491 
small molecule inhibitor (SMI) treatment strategies.
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RESULTS
Immunohistochemistry
Seventy three patients with pancreatic ductal 
(n=62) and ampullary (n=11) cancer were included in 
the study cohort with a control set of 24 patients with 
benign pancreatic disease. Immunohistochemical analysis 
showed markedly higher expression levels of Cdc7 
protein in pancreatic ductal and ampullary cancers when 
compared with benign pancreatic disease, in which Cdc7 
was detected in only very small numbers of cells (median 
LI 34.3%, IQR 28.6 to 63.4% vs. median LI 1.3%, IQR 
0.3 to 2.9%; P<0.0001) (Figure 2).
It was found that when the Cdc7 levels were 
assessed in biopsy samples and in resection samples 
for pancreatic cancer, higher expression was seen in the 
resection samples. To explain this. it was noted that in 
biopsy specimens there was often only a small amount 
of tumour tissue included, surrounded by stroma and 
inflammatory cells. As the protocol was to identify the 
regions with the highest expression and to photograph 
these (‘hot-spot’ technique), there may have been 
significant sampling error in the biopsy only specimens. 
Analysis was thus carried out following adjustment for 
several potential confounding variables (age, sex, tumour 
differentiation, ampullary vs. pancreatic ductal origin, 
resection status presence of metastatic disease). The 
association between Cdc7 expression and patient survival 
was examined for a 10-point increase in labeling. No 
association was seen between the Cdc7 labeling index and 
patient survival in the corrected analysis (Supplementary 
table).
Cdc7 expression was also compared to 3 other 
markers for cell cycle progression- Mcm2, geminin 
and phosphohistone H3. Spearman’s Rank correlation 
coefficient was used to assess the association between 
the markers with both biopsies and pancreatic resections 
included. All markers were strongly associated with 
one another, with P<0.0001 for each correlation 
(Supplementary Figure 1). Importantly, Cdc7 was found 
to be strongly positively correlated with the other markers, 
confirming that actively cycling cells have high levels of 
Cdc7 and that Cdc7 is a potential therapeutic target in 
pancreatic ductal and ampullary adenocarcinoma.
CDC7 knockdown in PANC-1 and Capan-1 
pancreatic adenocarcinoma cell lines
There was efficient Cdc7 mRNA knockdown 
in each cell line, with a mean reduction of 90% and 
95% after 48 hours, in PANC-1 and Capan-1 cells 
respectively, when compared to transfection with the 
control siRNA (Supplementary Figure 2). Cdc7 protein 
Figure 1: DNA origin activation checkpoint. The checkpoint response is dependent on three effector axes coordinated through the 
transcription factor FoxO3a. In arrested cells, FoxO3a activates the ARF-|Hdm2-|p53→p21 pathway and mediates p15(INK4B) upregulation. 
p53 in turn activates expression of the Wnt/β-catenin signalling antagonist Dkk3, leading to Myc and cyclin D1 downregulation. The 
resulting loss of CDK activity inactivates the Rb-E2F pathway resulting in G1 arrest. The lack of redundancy between the checkpoint axes 
and reliance on several tumour suppressor proteins commonly inactivated in human tumours provides a mechanistic basis for the cancer-
cell-specific killing observed following targeting of Cdc7. Notably multiple core components of this checkpoint pathway are mutated in 
pancreatic cancer (circled in red) thus sensitizing this tumour type to Cdc7 directed agents (adapted from Tudzarova et al, EMBO J. 2010 
Oct 6;29(19):3381-94, Figure 6).
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levels were also reduced to an undetectable level as 
assessed by western blot, as was Mcm2 phosphorylated 
on serine 53, which serves as a biomarker for Cdc7 
functionality (Figures 3A-3E and Supplementary Figure 
3A-3E). Next the effect of Cdc7 depletion in both lines 
was assessed by FACS flow cytometry. In Figure 3B and 
Supplementary Figure 3B, DNA histograms of the CDC7 
knockdown cells show the appearance of a sub-G1 peak 
of cells which had less than 2C DNA content. This 
effect became more pronounced over time and, after 96 
hours, 45% of PANC-1 and 51% of Capan-1 cells had 
accumulated in the sub-G1 peak, compared with less 
than 3% of control cells.
When protein levels were analysed after 96 hours, 
there was reduced Cdc7-target phosphorylation of Mcm2 
on Serine 53, consistent with loss of kinase activity. 
Increased expression of the cleavage products of both 
PARP-1 (89 KDa) and Caspase-3 (17 KDa) was coupled 
to loss of Cdc7 kinase activity indicating induction of the 
classical apoptotic pathway (Figure 3E and Supplementary 
Figure 3E). The triggering of apoptotoic cell death was 
confirmed by the observation that H2A.X serine 139 
phosphorylation (known as γH2A.X), was found to be 
increased in the Cdc7 knockdown cells, compared with 
the control siRNA. H2A.X is phosphorylated at this site in 
response to DNA double strand breaks which occur during 
genotoxic stress [41, 42].
When viewed with a phase contrast microscope, 
cells treated with CDC7 siRNA appeared to lose their 
normal cell-cell interactions, exhibited widespread cell 
death, and became detached from the culture flasks 
(Figure 4). In Figure 3C and Supplementary Figure 
3C both CDC7 siRNA and CO siRNA cells stained 
for BrdU, but a much smaller proportion of the CDC7 
siRNA cells stained positive, indicating reduced 
synthesis of new DNA and consistent with DNA fork 
stalling in the presence of rate limiting levels of Cdc7 
kinase activity.
Two additional methods were used to specifically 
demonstrate apoptosis in the cells. Terminal deoxynucleotidyl 
transferase labelling (TUNEL) recognises nicks in the 
DNA molecule to which the TdT enzyme incorporates 
fluorescently labelled nucleotides. TUNEL staining occurs 
in cells in the later stages of apoptosis. In Figure 3D and 
Supplementary Figure 3D strong staining can be seen in the 
CDC7 siRNA treated cells, with all cells having at least some 
staining (DAPI used as nuclear stain). In contrast no staining 
in the CO siRNA treated cells was observed.
Figure 3F and Supplementary Figure 3F show 
Annexin V labelled cells quantified using flow cytometry. 
Annexin V recognises the phospholipid phosphatidylserine 
which is translocated onto the outer cell membrane as an 
early event following the triggering of apoptosis in cells. 
75% and 64% (PANC-1 and Capan-1 respectively) of 
the Cdc7 depleted cells were found to stain positively 
for Annexin V, compared to approximately 10% of cells 
treated with control siRNA.
Cells were also treated with an alternative CDC7 
siRNA to control for a non-target effect shown in the 
original experiments (data not shown). CDC7 knockdown 
Figure 2: Immunohistochemistry of benign A. and malignant B. pancreatic tissue showing Cdc7 staining. C. Box and 
whisker plot showing that the Cdc7 labelling index (LI) in patients with pancreatic cancer was significantly higher than in those who had 
resections for benign disease (P<0.0001).
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with the alternative siRNA also showed efficient reduction 
in mRNA levels and protein analysis by western blot 
showed the same phenotypic pattern as with the original 
siRNA, with appearance of cleaved PARP-1, cleaved 
Caspase-3 and γH2A.X; confirming induction of the 
classical apoptotic cascade and DNA double-strand 
breaks. FACS analysis demonstrated that Cdc7 depletion 
with the alternative siRNA resulted in development of a 
strong sub-G1 peak, compared to a negligible proportion 
of cells treated with a non-coding control. These results 
show that the effect of Cdc7 depletion using 2 different 
CDC7 siRNAs have the same functional effect on these 
cell lines.
CDC7 knockdown in IMR-90 cell line
To confirm previous observations that untransformed 
cells would exhibit a G1 arrest in response to CDC7 
knockdown, the IMR-90 human diploid fibroblast line 
derived from fetal lung tissue was used. There was efficient 
knockdown of CDC7 mRNA when using 10 nM CDC7 
siRNA in IMR-90 fibroblasts. mRNA levels were reduced 
by a mean of 83% in these experiments, as demonstrated by 
qRT-PCR. Western blotting confirmed loss of Cdc7 protein 
expression at each concentration used, with undetectable 
protein by 72 hours (Figure 5A). In parallel with these 
observations, Mcm2 was found to be hypophosphorylated 
Figure 3: Knockdown of CDC7 mRNA in PANC-1 pancreatic adenocarcinoma cells following transfection with custom 
siRNA. A. Western blot showing Cdc7 protein expression levels following transfection with different concentrations of CDC7 siRNA 
(10, 50 and 100 nM) along with untreated (UT) and non-coding siRNA (CO). There was evidence of reduced protein expression at each 
concentration and at each time point. β-Actin loading control is shown below. B. Flow cytometry showing that at 48 hours, there was 
no enrichment of PANC-1 cells in the G1 population following treatment with 10 nM CDC7 siRNA, and cells started to accumulate in 
a sub G1 peak. At 96 hours this effect was more pronounced with evident cell death, as represented by the sub G1 peak of 45% and plot 
of distribution including examples of gating. C. BrdU staining (green) in cells treated with 10 nM CDC7 siRNA and CO siRNA. A much 
smaller proportion of the CDC7 siRNA cells stained positive, indicating reduced synthesis of new DNA. PI staining (red) is shown as 
a control. D. There was avid TUNEL staining (green) of 10 nM CDC7 siRNA treated cells indicating apoptosis. DAPI staining (blue) 
is shown as a control. E. Western blot showing protein levels at 96 hours following Cdc7 depletion with 10 nM siRNA in the PANC-1 
pancreatic adenocarcinoma cell line. There was reduced expression of Cdc7 protein and also loss of Cdc7 target phosphorylation of Mcm2 
at Ser53. There was evidence of activation of the classical apoptotic pathway with cleavage of PARP-1 and Caspase-3. Phosphorylated 
γH2A.X was seen after Cdc7 depletion suggesting double strand DNA breaks. F. Annexin V staining confirmed apoptosis (early and late) 
in 8% of CO siRNA treated cells (upper graph), compared with 75% of the 10 nM CDC7 siRNA treated cells (lower graph).
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on serine 53 when compared to control cells, confirming 
the reduced functional effect of Cdc7 kinase. There 
was minimal detection of cleaved PARP-1 at 89 KDa 
(none detectable at 10 nM) and no expression of 
cleaved Caspase-3 or of γH2A.X (Figure 5B). On phase 
contrast microscopy, cells showed significantly reduced 
confluency when compared to the control cells (Figure 
4). BrdU staining was almost absent in CDC7 siRNA, 
indicating a powerful G1 cell cycle arrest and failure of 
progression into S phase (Figure 5C). In keeping with these 
observations there was a complete absence of staining by 
the TUNEL assay indicating that these cells remain viable 
in this arrested state and confirming previous studies with 
untransformed cells lines (Figure 5D).
FACS flow cytometry showed that, in the CDC7 
siRNA treated cells, there was a functional cell cycle arrest 
with 85% of cells accumulating in G1 phase, and with only 
1% and 9% progressing through to S and G2/M phases 
respectively (Figure 5E and 5F). This was in contrast with 
CO siRNA treated cells in which 59% of the population 
were in G1 phase, with 14% in S phase and 26% in G2/M 
phases. Only a small fraction of cells was observed with a 
sub-G1 peak (5% and 1%, respectively).
Treatment of pancreatic adenocarcinoma cell 
lines and IMR-90 fibroblasts with the Cdc7/
Cdk9 kinase inhibitor PHA-767491
Reduced levels of Mcm2 serine 53 phosphorylation 
was observed at all PHA-767491 drug concentrations in 
both pancreatic cancer cell lines and IMR-90 fibroblasts 
96 hours following treatment with the inhibitor. Mcm2 
Figure 4: Phase contrast light microscopy of PANC-1, Capan-1 or IMR90 cells treated with either siRNA or 
PHA-767491, compared with controls. Images of cells obtained at 200X magnification using a Zeiss AxioObserver A1 microscope. 
96 hours following treatment with either CO siRNA, DMSO control or untreated typically growing PANC-1, Capan-1 and IMR90 cells 
were seen (representative images shown as a control). Following treatment with CDC7 siRNA or PHA-767491 the cancer cells became 
detached from the culture vessel and were seen freely floating within the media. In contrast IMR90 cells treated with CDC7 siRNA or PHA-
767491 did not change their morphology but instead appeared to arrest growth with no increase in population.
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protein phosphorylation became undetectable by western 
blot analysis at the 10uM concentration in PANC-1, 
and at the 2 μM concentration in Capan-1 and IMR-
90; these concentrations were therefore used for further 
experiments. In Figure 6A, western blots are shown 
for each cell line. In the Capan-1 and PANC-1 cells, 
western blotting showed similar results to the CDC7 
siRNA-treated cells with increased expression of cleaved 
PARP-1 and Caspase-3 (89 KDa and 17 KDa fragments 
respectively), as well as induction of γH2A.X expression, 
a marker of advanced DNA fragmentation. IMR-90 cells, 
as in previous experiments with CDC7 siRNA, showed no 
evidence of activation of the apoptotic machinery.
TUNEL staining was again strongly positive in the 
Capan-1 and PANC-1 treated cells, but absent in the IMR-
90 and DMSO treated control cells, consistent with the 
findings from flow cytometry (Figure 6B). Phase contrast 
microscopy showed widespread cell death of both PANC-
1 and Capan-1 cells treated with PHA-767491. In contrast, 
IMR-90 cells treated with either PHA-767491 or CDC7 
siRNA exhibited normal cell morphology but a much 
smaller population of cells was observed compared with 
controls consistent with a viable G1 cell cycle arrest as 
observed in previous studies (Figure 4) [19, 21, 23].
In Figure 6C, the proportion of cells in sub-G1 phase 
is shown on a bar chart for each cell line, showing that 
by 96 hours there Cdc7 kinase inhibition was associated 
with marked cell death in both the Capan-1 and PANC-1 
cell lines at 96 hours, indicated by the accumulation of 
cells with a sub-G1 DNA content, around 70% and 49% 
for the two pancreatic cell lines respectively at the 10uM 
concentration. Interestingly a dose dependent increase 
Figure 5: Knockdown of CDC7 mRNA in IMR90 fibroblast cells following transfection with custom siRNA. A. Western 
blot showing Cdc7 protein expression levels following transfection with different concentrations of CDC7 siRNA (10, 50 and 100 nM) 
along with untreated (UT) and non-coding siRNA (CO). There was evidence of reduced protein expression at each concentration and at 
each time point. β-Actin loading control is shown below. B. Western blot showing protein levels at 96 hours following Cdc7 depletion in the 
IMR90 fibroblast cell line. There was reduced expression of Cdc7 protein and also loss of Cdc7 target phosphorylation of Mcm2 at Ser53. 
In contrast to the changes seen in the cancer cells, there was no evidence of activation of the classical apoptotic pathway with no staining 
for cleaved PARP-1, Caspase-3 or γH2A.X. C. BrdU assay demonstrated reduced staining of the CDC7 siRNA treated cells (top images, 
green) when compared with propidium iodide (bottom images, red), whereas the control siRNA cells stained for both BrdU and PI. These 
findings indicate reduced synthesis of new DNA when the cells were treated with CDC7 siRNA. D. TUNEL assay showed no evidence 
of TUNEL labelling in CO siRNA or CDC7 siRNA treated cells (DAPI top, blue; TUNEL bottom, green). This assay was performed at 
the same time and under the same conditions as CDC7 siRNA treatments of PANC-1 and CAPAN-1 cells, which served as the positive 
control. On FACS analysis, treatment of IMR-90 fibroblasts with CDC7 siRNA F. induced an accumulation of cells in the G1 population, 
compared to CO siRNA treated cells E. (85% vs. 59%). There was a minimal sub-G1 peak (5% vs. 1%) seen. These findings suggest that 
Cdc7 depletion causing a G1 arrest in IMR90 cells.
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Figure 6: Effect of treatment with PHA-767491 on Capan-1, PANC-1 and IMR90 cell lines. A. Western blot showing protein 
levels at 96 hours following Cdc7/Cdk9 inhibition in each cell line. There was loss of Cdc7 target phosphorylation of Mcm2 at Ser53 in all 
lines. There was evidence of activation of the classical apoptotic pathway with cleavage of PARP-1 and Caspase-3 in the pancreatic cancer 
lines, but not in IMR90. Furthermore, in the cancer lines, phosphorylated γH2A.X was seen after treatment with the inhibitor suggesting 
double strand breaks in DNA, but not in IMR90. β-Actin loading control is shown below for each cell line. B. TUNEL staining (green) 
was strongly positive in the Capan-1 (2 μM PHA-767491) and PANC-1 (10 μM PHA-767491) cells but absent in the IMR90 treated cells 
(2 μM PHA-767491). DAPI staining (blue) is shown as a control. C. The proportion of cells in sub-G1 phase after 96 hours is shown on a 
bar chart for each cell line. Capan-1 shows high levels of sub-G1 accumulation at all dosages but in the PANC-1 line, there appeared to be 
a clear dose-dependent increase in the percentage of cells accumulating in the sub G1 peak (2 μM-15%, 5 μM- 22%, 10 μM- 49%) versus 
the DMSO and untreated controls.
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in cancer cell killing was observed for the PANC-1 
cell line corresponding to the dose dependent decrease 
observed in Mcm2 serine53 phosphorylation. In contrast, 
untransformed IMR-90 cells treated with PHA-767491 
showed minimal cell death with the majority of cells 
arrested in the G1 peak, mirroring the G1 cell cycle arrest 
observed with Cdc7 siRNA (Figure 5) and in keeping with 
previous studies [19, 21, 23].
DISCUSSION
The target validation and proof of concept studies 
conducted here have identified Cdc7 kinase and the 
associated DNA origin activation checkpoint as a 
promising new therapeutic point in pancreatic cancer. We 
have shown via immunohistochemistry that pancreatic 
cancer specimens contain significantly higher expression 
levels of the target protein Cdc7 than resected tissue from 
patients with benign pancreatic disease. Furthermore, we 
have also shown that the expression of Cdc7 strongly 
correlates with 3 other markers for cell cycle progression 
(Mcm2, geminin and phosphohistone H3) in pancreatic 
cancer. Following CDC7 knockdown with siRNA, 
pancreatic adenocarcinoma cells undergo pronounced 
apoptotic cell death. These findings are in keeping with 
the cancer-cell-specific killing observed following Cdc7 
targeting in other malignancies including leukemia 
and breast, ovarian and colorectal cancers [19–22, 25]. 
The cell lines tested, PANC-1 and Capan-1, harbour 
mutations in the tumour suppressors TP53, CDKN2A, 
CDKN2B and CDKN1B encoding for p53, p14ARF and 
p16INK4A, p15INK4B and p27Kip1, key constituent proteins 
encompassing all three arms of the origin activation 
checkpoint and representing mutations commonly found 
in pancreatic adenocarcinoma (Figure 1). In response to 
loss of function of any of these effector proteins we have 
previously shown that there is abrogation of the DNA 
origin activation checkpoint [23]. This results in tumour 
cells circumventing the G1 arrest thereby progressing 
into an abortive S phase. In the presence of rate limiting 
levels of Cdc7 kinase, only a limited number of replication 
forks are established during S phase, culminating in fork 
stalling and/or collapse followed by apoptotic cell death 
[19–22]. Notably the potent cancer cell specific killing 
observed in pancreatic cancer following Cdc7 inhibition 
or depletion contrasts with the stable G1 arrest observed 
in untransformed normal human diploid fibroblasts (IMR-
90) with an intact DNA origin activation checkpoint and 
mirrors the G1 cell cycle arrest observed in previous 
studies with primary untransformed cell lines [9, 21, 23]. 
Moreover, we have also observed a stable reversible G1 
arrest in normal (HMEpC) and immortalised (MCF10A) 
human mammary (HMEpC) epithelial cells following 
Cdc7 depletion [19]. Taken together these data highlight 
the highly specific nature of the cancer-cell-specific 
killing following Cdc7 targeting and therefore make it a 
potentially powerful target in the treatment of advanced 
pancreatic cancer.
Interestingly, p53 inactivation not only abrogates 
the DNA origin activation checkpoint but also increases 
the Cdc7 protein expression levels of the target protein 
itself, thus potentially reinforcing therapeutic efficacy 
through a positive feedback loop [24]. Intriguingly we 
have now discovered the mechanism linking loss of p53 
function to increased Cdc7 levels. We have shown that 
p53 is a negative regulator of Cdc7 and that this linkage 
is part of the generalized p53 cellular stress response. 
Following genotoxic insult it is well established that p53 
levels increase resulting in induction of p21 which blocks 
DNA replication initiation through inhibition of CDK2 
function. We have now shown that a parallel effector 
pathway blocks DNA replication initiation by lowering 
Cdc7 levels. We have discovered that p53 controls Cdc7 
stability post-transcriptionally via miR-192/215 and post-
translationally via Fbxw7β E3 ubiquitin ligase (Tudzarova 
et al, manuscript submitted). Thus loss of p53 function 
attenuates this negative regulation of Cdc7 levels and is 
thus in keeping with the observation that Cdc7 levels are 
raised in p53 mutant tumours [24].
In summary, we have shown that Cdc7 kinase 
is highly expressed in pancreatic adenocarcinoma and 
therefore a potentially attractive target in this tumour 
type. Furthermore, targeting of Cdc7 in pancreatic 
cancer cell line model systems with either CDC7 siRNA 
or alternatively Cdc7 SMI inhibitors can induce potent 
cancer cell-specific killing. Targeting Cdc7 using either of 
these modalities therefore offers new exciting therapeutic 
opportunities for the treatment of this aggressive disease 
for which treatment options are presently limited.
MATERIALS AND METHODS
Immunohistochemistry
Between 1/1/2005 and 1/1/2010 all patients who had 
had a biopsy or surgical resection sample of pancreatic 
tissue at University College Hospital, London were 
identified using the CoPath histology database (Sunquest, 
Tucson AZ, USA). Patients were excluded if the sample 
was inadequate for immunohistochemistry or if clinical 
data were not available. Formalin fixed paraffin embedded 
(FFPE) tissue blocks of representative tumour or benign 
tissue were obtained, and consecutive serial tissue 
sections were cut at a thickness of 4 μm onto Superfrost 
Plus slides (Visions Biosystems, Newcastle Upon Tyne, 
UK), dewaxed in xylene and rehydrated through graded 
alcohol to water. The tissue sections were pressure-
cooked in 0.1 M citrate buffer at pH 6.0 for 2 minutes and 
immunostained using the Bond Polymer Refine Detection 
kit and Bond-III automated system (Vision Biosystems).
Primary antibodies were applied at the following 
dilutions: Mcm2 (1:1000), geminin (1:150), H3p (1:3000) 
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and Cdc7 (1:100). Mcm2 monoclonal antibody (clone 
46) was obtained from BD Transduction Laboratories 
(Lexington, KY, USA), Geminin monoclonal antibody 
from Leica Microsystems (Newcastle Upon Tyne, UK), 
Histone H3 phosphorylated on Serine 10 (H3p) polyclonal 
antibody from Upstate (Lake Placid, NY, USA), Cdc7 
monoclonal antibody from MBL International (Woburn, 
MA, USA).
The slides were dehydrated with graded alcohol and 
then washed thrice with xylene (100% concentration). 
Incubation without a primary antibody was used as a 
negative control and tonsil epithelial sections as positive 
controls. Slides were initially evaluated at low-power 
magnification (100x) to identify the regions of tumour 
with the highest intensity of staining. From these selected 
areas, 3-5 fields at 400x magnification were captured with 
a charged-coupled-device camera and analysis software 
(SIS, Munster, Germany). Images obtained were printed 
in colour for quantitative analysis. After blinding for 
knowledge of clinicopathological variables, both positive 
and negative cells were counted within each field and 
stromal and inflammatory cells excluded. A minimum 
of 500 cells were counted for each case. The Labelling 
Index (LI) was then calculated for each marker using the 
following formula: LI= number of positive cells/total 
number of cells x100. Local research ethics committee 
approval was obtained from the joint UCL/UCLH 
Committees on the Ethics of Human Research (REC 
reference 06/Q0512/106).
Cell culture experiments
Human pancreatic adenocarcinoma cell lines PANC-
1 (ATCC; CRL-146) and Capan-1 (Capan-1 (ATCC; 
HTB-79), as well as the normal IMR-90 fibroblast line 
(ATCC; CCL-186) were used. The PANC-1 and Capan-1 
pancreatic adenocarcinoma cell lines were selected as they 
represent cell line model systems representative of the 
majority of pancreatic cancers harbouring point mutations 
in the TP53 gene as well as inactivating mutations in 
the tumour suppressor genes CDKN2B, CDKN2A and 
CDKN1B [26, 34–38]. Cells were cultured in BD Falcon 
(Franklin Lakes, NJ, USA) T75 flasks or six-well plates 
in a 5% CO2 incubator at 37°C. The medium used for 
culture was DMEM+ GlutaMAX™ High Glucose 
(Gibco, Invitrogen, Grand Island, NY, USA) and fetal 
bovine serum (Gibco) was added at a concentration of 
10% (PANC-1 and IMR-90) or 20% (CAPAN-1). Each 
treatment experiment was carried out in triplicate.
RNA interference
For CDC7 siRNA treatment, a custom double-
stranded siRNA with sequence: sense strand 
5’-GCUCAGCAGGAAAGGUGUUUU-3’ and antisense 
strand 5’-AACACCUUUCCUGCUGAGCUU-3’ 
(Dharmacon, Thermo Scientific, Lafayette, CO, 
USA) was used, with non-targeting siRNA (Ambion, 
Invitrogen, Grand Island, NY, USA) as a negative 
control. To control for a non-target effect, an alternative 
CDC7 siRNA was also used with the sequence: sense 
strand 5’-GCTCAGCAGGAAAGGTGTTTT-3’ and 
antisense strand 5’-AACACCTTTCCTGCTGAGCTT-3’ 
(Dharmacon, Thermo Scientific, Lafayette, CO, USA). For 
the PANC-1 and IMR-90 lines, siRNA was diluted to 10, 
50 and 100 nM concentrations in Opti-MEM (Gibco), and 
complexed with lipofectamine RNAiMAX (Invitrogen, 
Grand Island, NY, USA) according to the manufacturer’s 
instructions. Due to poor efficacy of standard transfection 
reagents in the Capan-1 cell line, transfection was 
carried out via electroporation using the Amaxa Cell 
Line Nucleofector Kit V (Lonza Cologne AG, Cologne, 
Germany) with 50 and 100 nM siRNA, according to the 
manufacturer’s instructions [39].
Cdc7 inhibitor treatment
The Cdc7/Cdk9 inhibitor PHA-767491 was supplied 
as a powder which was resolved in the solvent dimethyl 
sulfoxide (DMSO). In these experiments, PHA-767491 
was added to the medium at concentrations of 2, 5, or 10 
μM and DMSO alone was used as a control. Cells were 
then reincubated at 37°C in a CO2-controlled incubator 
and harvested at the defined time points as indicated 
above.
RNA isolation and quantitative real-time  
(qRT)-PCR
Following collection of the cells, total RNA 
was extracted using the Purelink RNA mini kit 
(Ambion, Invitrogen, Grand Island, NY, USA) 
according to the manufacturer’s instructions. 
The exon-flanking primer set for Cdc7 (forward, 
5’-AACTTGCAGGTGGTAAAAAG-3’; and reverse, 
5’-TGAAAGTGCCTTCTCCAAT-3’) was generated 
using PrimerQuest (IDT, Coralville, IA, USA) and 
supplied by Eurofin Genomics (Ebersberg, Germany). 
Using the Superscript III Platinum SYBR Green One 
Step qRT-PCR kit (Invitrogen, Grand Island, NY, USA), 
RNA was reverse transcribed and amplifyed in one 
step. Fluorescent PCR products were detected using 
the Mastercycler ep Realplex 4 (Eppendorf, Hamburg, 
Germany). The qRT-PCR protocol was as follows: a single 
cDNA synthesis step case was performed at 50°C for 3 
minutes; followed by a single denaturation step at 95°C for 
10 minutes; then 45 cycles of denaturation at 95°C for 15 
seconds, annealing at 47°C for 20 seconds and extension 
at 60°C for 20 seconds. The Eppendorf Realplex Detection 
System Software (Eppendorf, Hamburg, Germany) was 
used to determine Cycle threshold (Ct) values. GAPDH 
measurements were used to normalize the data and the 
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relative expression of CDC7 RNA in treated samples to 
untreated samples was determined.
Immunoblotting
For western blot analysis, cells were harvested and 
lysed in modified RIPA buffer (50 mM Tris–HCl, 300 mM 
NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 
1 mM EDTA and cOmplete Mini EDTA-free protease 
inhibitor cocktail by Roche Life Science) for 45 min 
on ice and then sonicated for 10 seconds as previously 
described [23]. Protein concentration was determined 
using the Bio-Rad DC protein assay (Bio-Rad, Hercules, 
CA, USA) according to the manufacturer’s instructions. 
Protein concentrations were analysed in comparison to 
a pre-prepared standard curve using a MDS Analytical 
Technologies SpectraMax MZ plate reader (Molecular 
Devices, Sunnyvale, CA, USA). Following denaturing, 
samples containing 40 μg total protein were loaded into 
each well with gel loading buffer onto Novex 4-20% Tris-
Glycine 1.5 mm, 15 well gels (Invitrogen, Grand Island, 
NY, USA). Blocking, antibody incubations and washing 
steps were performed as described [40]. Protein was 
transferred onto Amersham Biosciences Hybond-C Extra 
membranes (GE Healthcare, Buckinghamshire, UK) by 
semi-dry electroblotting at 15V for 60 minutes, according 
to the manufacturer’s instructions and developed using 
ECL Chemiluminescent Substrate Reagent Kit (Invitrogen, 
Grand Island, NY, USA).
Immunoblotting antibodies
Mcm2 phospho Serine (Ser) 53 polyclonal 
antibody was obtained from Bethyl Laboratories 
(Montgomery, TX, USA) and used at a concentration 
of 1:500; Cdc7 monoclonal antibody (clone DCS-342) 
from MBL International (Woburn, MA, USA) and used 
at a concentration of 1:1000; caspase 3 (CPP32 4-1-18) 
monoclonal antibody from Novus Biologicals (Littleton, 
CO, USA) and used at a concentration of 1:1000; cleaved 
caspase 3 (Asp175) polyclonal antibody from Cell 
Signaling Technology Inc. (Danvers, MA, USA) and 
used at a concentration of 1:1000; PARP-1/2 (H-250) 
polyclonal antibody from Santacruz Biotechnology (Santa 
Cruz, CA, USA) and used at a concentration of 1:1000; 
Phospho-Histone H2A.X (Ser139) Antibody from Cell 
Signaling Technology Inc. (Danvers, MA, USA) and used 
at a concentration of 1:1000; β-actin from Sigma Aldrich 
(St. Louis, MO, USA) and used at a concentration of 
1:5000.
Cell sorting (FACS analysis)
Following collection, the cells were pelleted 
and fixed in 80% methanol at -20°C for at least 1 hour. 
Prior to FACS, cells were incubated with FACS solution 
containing 50 ug/ml propidium iodide (PI) and 50 ug/ml 
RNase A at 37°C for 1 hour and then sorted on a Beckman 
Coulter CyAN ADP flow cytometry system (Beckman 
Coulter Inc., Orange County, CA, USA). The forward 
scatter signal was used to trigger the detection of cells 
and the PI signal fluorescence was linearly quantified to 
rationalise DNA after excitation at 488 nm. PI fluorescence 
was detected on the FL3/PE-Texas Red detector (613/20 
nm band pass filter). Gating was carried out as described 
to discount any surviving non-diploid cells.
BrdU cell proliferation assay
Cells were cultured on coverslips in 6-well plates 
and treated as described above. Treated or control cells 
were pulsed with 100 μM 5-bromo-2’-deoxyuridine 
(BrdU) (Sigma Aldrich, St. Louis, MO, USA) for 1 hour 
prior to harvesting. Coverslips were then washed in 1 ml 
PBS and fixed with 4% paraformaldehyde. The cells were 
permeabilised in 0.2% Triton X for 5 minutes and 2N 
HCl was added for 1 hour to denature the cellular DNA. 
Coverslips were incubated in the dark at 37°C with 20 μg/
ml fluorescein conjugated anti-BrdU antibody (Millipore, 
Temecula, CA, USA), 50 ng/ml PI solution and 50 ng/ml 
RNaseA. The coverslips were mounted onto slides and the 
cells examined with a Leica TCS SP confocal microscope.
TUNEL assay
The terminal deoxynucleotidyl dUTP nick end 
labelling (TUNEL) assay was used for determining 
apoptosis in the cultured cells. Cells were grown on 
coverslips in 6-well plates and treated as described above. 
Coverslips were removed from the cell media at the 
designated time points fixed in 1% paraformaldehyde. 
Cells were permeabilised by submersion in precooled 
ethanol and acetic acid in a 2:1 mix for 5 minutes at 
-20°C. The ApopTag Fluorescein Direct In Situ Apoptosis 
Detection Kit (Chemicon, Millipore, Temecula, CA, 
USA) was then used according to the manufacturer’s 
instructions. The coverslips were counterstained using PI 
solution and mounted onto glass slides for analysis with 
the Leica TCS SP confocal microscope.
Annexin V assay
The Annexin V assay was carried out using the 
Millipore Muse Cell Analyser (Millipore, Temecula, 
CA, USA), according to the manufacturer’s instructions. 
Briefly, 100 μg/ml cells were pelleted, before adding 
100 μl of Annexin reagent and incubated in the dark for 
20 minutes at room temperature. Annexin V labelled cell 
counts were then carried out in an automated fashion by 
the Muse Cell Analyser.
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